UBS Initiates Coverage on Novo Nordisk (NVO) with a Neutral
More News related to NVO
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- FDA Approves 10 mcg Dose of Vagifem(R) for the Treatment of Atrophic Vaginitis Due to Menopause
- Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
- Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
- Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show
More News related to New Coverage
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
UBS initiates coverage on Novo Nordisk (NYSE: NVO) with a Neutral.
Novo Nordisk A/S is a Denmark-based healthcare company. The Company provides diabetes care and has diabetes product portfolio in the industry, including insulin delivery systems.
Related Categories
New CoverageStocks Mentioned
-0.55Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
